← stocks-llm Find companies like TECX →

TECTONIC THERAPEUTIC INC (TECX)

Health Care · Clinical-stage GPCR-targeted biologic therapeutics · NASDAQ

A clinical-stage biotech developing novel GPCR-targeting biologics for rare pulmonary and bleeding disorders using its proprietary GEODe platform.

What TECTONIC THERAPEUTIC INC does

Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate the activity of GPCRs (G-protein coupled receptors). The company has developed a proprietary technology platform called GEODe to enable the discovery of GPCR-targeted biologic medicines targeting diseases with significant unmet medical need. Its lead product candidates are TX45, an Fc-relaxin fusion molecule for pulmonary hypertension, and TX2100, a VHH-Fc fusion antagonist antibody for hereditary hemorrhagic telangiectasia.

Themes: ["GPCR-targeted therapeutics","Pulmonary hypertension / heart failure","Hereditary hemorrhagic telangiectasia (HHT)","Interstitial lung disease (ILD)","Rare genetic bleeding disorders"]

Fundamentals

Ask why TECX looks like this →

Key risks (from latest filing)

["Clinical development risk: Lead programs TX45 and TX2100 are in Phase 2 and Phase 1a trials respectively, with no guarantee of success or regulatory approval.","Capital requirements: As a pre-revenue clinical-stage company, Tectonic requires significant ongoing funding to support drug development, clinical trials, and operations.","GPCR modulation complexity: The discovery and development of biologics that can modulate GPCRs has historically been challenging, and the company's platform may not overcome these inherent technical barriers."]

See TECX's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.